Oxford Ledge
Search
Market prices for DFTX are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Definium Therapeutics, Inc. (NASDAQ: DFTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:22 UTC.
The company is a clinical-stage biopharmaceutical developer focused on treating brain health disorders using pharmaceutically optimized psychedelic and empathogen compounds. Its lead product candidate, DT120, a form of lysergide, is being developed for generalized anxiety disorder and major depressive disorder, with Phase 2b results published in a medical journal and FDA breakthrough designation granted for anxiety. The company is advancing DT120 into Phase 3 clinical trials with multiple studies in both anxiety and depression expected to produce results in 2026.
Summarized from Definium Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for DFTX and 5,000+ tickers.
Create a free account — keep DFTXGET /api/data?ticker=DFTX
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt